Navigation Links
Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
Date:6/9/2008

Initial Trial Results Expected in Q3 2008 Conference Call to be Held on Monday, June 9, 2008 at 5:15 p.m. Eastern

Time

MOUNTAIN VIEW, Calif., June 9 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has completed enrollment of its first Phase 3 clinical trial with AZ-004 (Staccato(R) loxapine). AZ-004 is an inhalation product candidate being developed for the treatment of acute agitation in patients with schizophrenia or bipolar disorder. Alexza believes the novel, non-invasive nature and rapid pharmacokinetic (PK) properties resulting from inhaled loxapine administration via the Staccato system have the potential to make AZ-004 a viable product to treat acute agitation. AZ-004 is being developed through Symphony Allegro, a product development partnership formed between Alexza and Symphony Capital, LLC in 2006.

"We initiated this first Phase 3 clinical trial of our lead program in late February, completed enrollment in less than four months, and project to have initial results in late September, which is six months ahead of our original schedule," said James V. Cassella, PhD, Alexza Senior Vice President, Research and Development and chairman of the Symphony Allegro Development Board. "We are pleased at the pace this trial enrolled and believe this indicates clinician enthusiasm for this novel drug candidate."

"With the early completed enrollment of our first AZ-004 Phase 3 study, we are sharpening our focus and accelerating our AZ-004 pre-commercialization activities for manufacturing, quality systems, regulatory submissions, and potential sales and marketing," said Thomas B. King, Alexza President and CEO. "We also remai
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Avizia, Inc., a leading provider of cutting-edge ... equity financing round led by NextGen Angels along with ... will be used to continue to fuel the rapidly ... Edward Kennedy , CEO and president of Tollgrade ... Leonard Kurtzman , CFO of newBrandAnalytics, who joined the ...
(Date:8/19/2014)... MALVERN, Pa. , Aug. 19, 2014  SCILEX ... commercialization of late-stage pharmaceutical products for the treatment of ... composed of four members: Dr. Jeff Gudin , ... and Mr. Kip Vought . ... said the expertise of this board would greatly assist ...
(Date:8/19/2014)... Aug. 19, 2014 Luoxis Diagnostics, ... Inc. (NYSE MKT: AMPE), today announced an ... Meeting of the American Academy of Surgical Trauma ... in Philadelphia, Pennsylvania that ... will report results from a recently completed five-year ...
Breaking Medicine Technology:Avizia Closes Funding Round 2SCILEX Pharmaceuticals Announces Scientific Advisory Board 2SCILEX Pharmaceuticals Announces Scientific Advisory Board 3SCILEX Pharmaceuticals Announces Scientific Advisory Board 4Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 3
... Calif., Dec. 21 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ... payment from OncoGenex Pharmaceuticals, Inc. (Nasdaq: OGXI ) ... Pharmaceutical Industries Ltd. ( TEVA). OGX-011 is a second-generation ... a successful Phase 2 program in patients with advanced prostate ...
... , SAN DIEGO, Dec. 18 LifeVantage Corporation ... Anti-Aging Cream, science-based solutions to oxidative stress, announced today that ... other parties, Zrii, LLC. Under the terms of this agreement, ... William Farley, on the one hand, and the Company and ...
Cached Medicine Technology:Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva 2Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva 3LifeVantage Announces Settlement of Zrii Litigation 2LifeVantage Announces Settlement of Zrii Litigation 3
(Date:8/20/2014)... Los Angeles, CA (PRWEB) August 20, 2014 ... specialization and a low availability of substitutes typify the ... buyer power score of 3.1 out of 5, indicating ... buyer power suggests buyers and suppliers have an equal ... research analyst Kayley Freshman-Caffrey. , First, few substitutes exist ...
(Date:8/20/2014)... August 20, 2014 First Choice ... emergency rooms in the United States, named Richard Daniels, ... FM 685 facility. , “We are pleased to ... director of our second facility in Pflugerville,” said Dr. ... Emergency Room. , Dr. Daniels received his undergraduate ...
(Date:8/20/2014)... 20, 2014 Kowa Optimed returns after ... to debut the new SL-17 portable slit lamp. , ... white LED source controlled by an illuminated thumb wheel ... SL-17 uses commercially available AAA rechargeable and dry cell ... design requiring batteries designed specifically for the device. The ...
(Date:8/20/2014)... August 20, 2014 This agreement ... of software defined networking, high availability cloud enablement, ... of Resellers, while allowing OPEN-V to sell storageFOUNDRY’s ... pleased to work with OPEN-V on this distribution ... Hows, manager distribution channels at storageFOUNDRY. "Nautilus is ...
(Date:8/19/2014)... 2014 Midtown Dentistry in Houston, Texas, is ... All patients with cavities, or with old fillings that ... that can safely repair and restore teeth. , From now ... materials, all of which are completely amalgam free. Even though ... by the FDA for adults and children over the age ...
Breaking Medicine News(10 mins):Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 3Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 4Health News:First Choice Emergency Room Announces Dr. Richard Daniels as Medical Director of the Pflugerville – FM 685 Facility 2Health News:Kowa Optimed (Booth MS13043) to Debut New Portable Slit Lamp at 2014 Vision Expo West in Las Vegas, Nevada 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 3Health News:Midtown Dentistry Announces It Is Now an Amalgam-Free Office 2
... Health System set out to reduce energy consumption, they weren,t ... at healthcare facilities. Instead, they,re aiming for a 20 percent ... metric tons of carbon dioxide annually that,s not being released ... the road. The La Crosse, Wis.-based health system is on ...
... a statement by UNITE HERE General President Bruce Raynor:Contrary ... press contact, today,s General Executive Board meeting ended with ... President of UNITE HERE. To be crystal clear: I ... authorized Wilhelm to discuss this issue with me.(Logo: ...
... Only two percent of hospitals nationwide receive Magnet ... Center (ANCC) has announced that Baylor University ... earned re-designation as a Magnet hospital, effective immediately. ... been designated at a Magnet hospital, and merely ...
... Pharmos Corporation (Pink Sheets: PARS) announced today that ... and warrants. At the closing, the Company issued ... an additional 18,000,000 shares of common stock for an ... of the warrants, which have a five-year term, is ...
... 2009 (BRONX, NY) Recurrent and metastatic endometrial ... They have spread to other organs and typically have ... with chemotherapy may not be able to endure more ... of Yeshiva University have shown that a combination of ...
... Exposition Park LOS ANGELES, ... of Dimes premier fundraising event that benefits all babies--those born ... 11,000 walkers are expected at this largest March for Babies ... Park, at the corner of S. Figueroa and 39th St., ...
Cached Medicine News:Health News:Innovative Program Will Help Lead Health System to Energy Independence by 2014 2Health News:Statement From UNITE HERE General President Bruce Raynor on Today's General Executive Board Meeting 2Health News:Baylor Dallas Nationally Recognized for Nursing Excellence 2Health News:Pharmos Completes Private Placement - Raises $1.8 Million 2Health News:Pharmos Completes Private Placement - Raises $1.8 Million 3Health News:New treatment shows promise against recurrent gynecologic cancers 2Health News:Farmers Insurance Joins March of Dimes March for Babies April 25, 2009 2
IBT Reference Laboratory is a national research and specialty clinical lab founded in 1983 that provides a wide range of tests and services in the area of allergy, clinical immunology and molecular b...
Marquette General Health System Reference Laboratory provides a full range of testing including, Chemistry, Hematology, Coagulation, Urinalysis, Microbiology, Cytology, Anatomic Pathology, Flow Cytom...
Headquartered in Burlington, North Carolina, LabCorp has more than 23,500 employees and offers more than 4,400 clinical tests ranging from routine blood analyses to the most sophisticated molecular d...
the LabOne Healthcare Group markets laboratory testing to physicians, patients, managed care companies, self-insured employers, wellness companies and hospitals....
Medicine Products: